


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A non-naturally occurring, biologically active compound having the formula F-A



where

R consists of at least one carbohydrate moiety and/or at least one Pet (pentaerythritol) unit, and optionally, one or more spacers, and optionally a trivalent or tetravalent linker;

Ch is chalcogen;

R<sup>2</sup> is hydrogen, or an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers;

R<sup>3</sup> is -CH<sub>2</sub>-R<sup>3'</sup> or -C(=Ch)-R<sup>3'</sup>, where R<sup>3'</sup> is an organic moiety consisting of a polyunsaturated moiety or a primarily alkyl moiety, and, optionally, one or more spacers, and optionally a trivalent or tetravalent linker,

A is CH<sub>2</sub>OH or is an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers; and

at least one of the following conditions applies:

(1) R3' consists of at least one polyunsaturated moiety and optionally one or more spacers;

(2) R3' is of the form -(trivalent or tetravalent linker)(-spacer-T<sup>a</sup>)<sub>a</sub>(-T<sup>b</sup>)<sub>b</sub>, where a and b are integers each in the range of 0-3, and a+b is in the range of 2-3, [[,]] and T<sup>a</sup> and T<sup>b</sup> are, independently, organic moieties consisting of at least one *primarily alkyl* moiety and, optionally, one or more *spacers*, which may differ for each of the a instances of T<sup>a</sup> and each of the b instances of T<sup>b</sup>; or

(3) A is -CH<sub>2</sub>OH;

each trivalent or tetravalent linker being, independently, an aliphatic moiety with not more than 12 non-hydrogen atoms, and consisting of one or more alkyl moieties and/or one or more spacers;

each spacer being selected independently from the group consisting of -NR\*- , -C(=O)- , -C(=S)- , -O- and -S- , wherein R\* is H or alkanyl of 1-4 carbons.

2. (Original) The compound of claim 1 where each of the organic moieties consists of not more than 120 atoms other than hydrogen atoms.

3. (Original) The compound of claim 1 where each chalcogen is oxygen.

4. (Original) The compound of claim 1 in which R2 is hydrogen.

5-6 (Cancelled).

7. (Original) The compound of claim 1 where condition (1) applies.

8-9 (Cancelled).

10. (Original) The compound of claim 1 where condition (2) applies.

11. (Previously Presented) The compound of claim 7 where the polyunsaturated moiety comprises at least one methylene-interrupted pair of alkenic double bonds ( $-C=C-C-C=C-$ ).

12. (Original) The compound of claim 11 where the carbon skeleton of R<sub>3</sub> is the same as the carbon skeleton of the fatty acyl moiety of arachidonic acid.

13 (cancelled).

14. (Previously Presented) The compound of claim 10 in which each T<sup>a</sup> and T<sup>b</sup> is an independently chosen primarily alkyl moiety.

15-16 (Cancelled).

17. (Original) The compound of claim 14 in which the linker is trivalent.

18. (Original) The compound of claim 17 in which R<sub>3</sub>' is of the form  $-CH_2-CH(-R_3'_{Rem2})-R_3'_{Rem1}$ , and R<sub>3</sub>'<sub>Rem1</sub> and R<sub>3</sub>'<sub>Rem2</sub> are independently chosen organic moieties consisting of at least one primarily alkyl moiety and, optionally, one or more spacers.

19. (Previously Presented) The compound of claim 17 in which R3' is of a form selected from the group consisting of


- CH<sub>2</sub>-CH(-R<sub>3b</sub>)-(spacerA<sub>1</sub>)-(spacerA<sub>2</sub>)-R<sub>3</sub>"
- CH<sub>2</sub>-CH(-R<sub>3b</sub>)-(spacerA)-R<sub>3</sub>"
- CH<sub>2</sub>-CH(-(spacerB)-R<sub>3b</sub>)-(spacerA<sub>1</sub>)-(spacerA<sub>2</sub>)-R<sub>3</sub>"
- CH<sub>2</sub>-CH(-(spacerB)-R<sub>3b</sub>)-(spacerA)-R<sub>3</sub>"
- CH(-R<sub>3b</sub>)-(spacerA<sub>1</sub>)-(spacerA<sub>2</sub>)-R<sub>3</sub>"
- CH(-R<sub>3b</sub>)-(spacerA)-R<sub>3</sub>"
- CH(-(spacerB)-R<sub>3b</sub>)-(spacerA<sub>1</sub>)-(spacerA<sub>2</sub>)-R<sub>3</sub>"
- CH(-(spacerB)-R<sub>3b</sub>)-(spacerA)-R<sub>3</sub>"

where each of spacerA, spacerA<sub>1</sub>, spacerA<sub>2</sub> and spacerB is an independently chosen spacer, and R<sub>3</sub>" and R<sub>3b</sub> are primarily alkyl moieties.

20. (Previously Presented) The compound of claim 19 in which SpacerA<sub>1</sub> is -NH- or -O-, Spacer A<sub>2</sub> is -C(=O)-, SpacerA is -O-, and SpacerB is -O-.

21-49 (Cancelled).

50. (Previously Presented) A compound defined by the following structure:




wherein R is chosen from structure I or II,




wherein  $R^3$  is a substitution group selected from the group consisting of


- (i)  $-\text{CO}(\text{CF}_2)_m\text{CF}_3$ ,
- (ii)  $-\text{COCF}_2(\text{CH}_2)_m\text{CH}_3$ ,
- (iii)  $-\text{CO}(\text{CH}_2)_k(\text{CH}=\text{CHCH}_2)_2(\text{CH}=\text{CHCH}_2)_n(\text{CH}_2)_m\text{CH}_3$ ,
- (iv)



(v)




(vi)




18

(vii)



and

(viii)




wherein M is  $\text{CH}_2$  or  $\text{CO}$ ; k and m are independent integers with values from 0 to 30, and n and p are independent integers with values from 0 to 10, and

$\text{R}^4$  is H or OH, and  $\text{R}^5$  is H; or  $\text{R}^4$  and  $\text{R}^5$  form a double bond.


51. (Original) The compound of claim 50, having the structure

USSN - 10/529,393




52-62 (Cancelled).

63. (Previously Presented) A non-naturally occurring, biologically active compound defined by the following structure:




wherein R3 is a substitution group selected from the group consisting of


- (i)  $-\text{CO}(\text{CF}_2)_m\text{CF}_3$ ,
- (ii)  $-\text{COCF}_2(\text{CH}_2)_m\text{CH}_3$ ,
- (iii)  $-\text{CO}(\text{CH}_2)_x(\text{CH}=\text{CHCH}_2)_2(\text{CH}=\text{CHCH}_2)_n(\text{CH}_2)_m\text{CH}_3$ ,
- (iv)



(v)




(vi)




18

(vii)





(viii)







. and


(ix)  $-\text{CO}(\text{CH}_2)_m\text{CH}(\text{OH})(\text{CH}_2)_k\text{CH}_3$ ,

wherein M is  $\text{CH}_2$  or  $\text{CO}$ ; k and m are independent integers with values from 0 to 30, and n and p are independent integers with values from 0 to 10.

64. (Previously Presented) The compound of claim 63 where the  $\text{R}_3$  therein has a structure selected from the group consisting of



65. (Original) The compound of claim 64 which has the structure



66-91 (Cancelled).

92. (Previously Presented) The compound of claim 160 where the carbohydrate moiety is a monosaccharide.

93. (Previously Presented) The compound of claim 160 where said carbohydrate moiety comprises at least one sugar unit which is hexosyl, pentosyl, or nonosyl.

94. (Original) The compound of claim 93 in which each sugar unit is hexosyl, pentosyl or nonosyl.

95. (Previously Presented) The compound of claim 94 in which each sugar unit is (a) galactose, glucose, mannose or fucose, (b) a deoxy or N-acetyl derivative of (a), or (c) a sialic acid.

96. (Previously Presented) The compound of claim 1 where the inner sugar unit is galactose.

97. (Original) The compound of claim 96 where the inner sugar unit is alpha-galactose.

98. (Original) A compound selected from the group consisting of compounds 1-5 in Fig. 11, 8-13 in Fig. 12, and 033 in Fig. 31.

99. (Currently amended) A pharmaceutically acceptable composition comprising at least one compound according to claim ~~205~~ 206.

100. (Currently Amended) The composition of claim 99, where said compound has ~~immunomodulatory~~ immunomodulatory activity, and further comprising at least one immunomodulatory agent which is not one of said compounds.

101. (Original) The composition of claim 100, where at least one such immunomodulatory agent is an immunogen.

102. (Previously presented) The composition of claim 100, where at least one such immunomodulatory agent is an adjuvant.

103. (Original) The composition of claim 102, where said adjuvant is selected from the group consisting of lipid A, lipid A analogues, CpG-containing oligonucleotides, muramyl dipeptides, sitosterols, alum, and QS-21.

104. (Original) The composition of claim 99, further comprising at least one antiviral, antibacterial, antiparasitic or antitumor agent other than said compound.

105. (Previously Presented) The composition of claim 99, in liposomal form.

106. (Cancelled)

107. (Currently Amended) A method of protecting a mammalian subject against a virus, microbial infection, parasite or cancer which comprises administering to the subject a pharmaceutically effective amount of a compound according to claim ~~205~~ 206 which has pharmaceutical activity against such virus, microbial infection, parasite, or cancer.

108. (Original) The method of claim 107 wherein protection is against a virus.

109. (Original) The method of claim 108 wherein said virus is HIV-1.

110. (Original) The method of claim 107 wherein protection is against a cancer.

111. (Original) The method of claim 110 which further comprises administration of an immunogen comprising a tumor-associated epitope.

112. (Original) The method of claim 111 where said immunogen comprises a MUC1 epitope.

113. (Original) The method of claim 111 where said immunogen comprises a Tn, TF, sialyl Tn, sialylTF, F1- $\alpha$ , Globo H, Fucosyl GM1, or GalNAc GM1 epitope.

114. (Original) The method of claim 110 wherein said cancer is a melanoma.

115. (Original) The method of claim 107 wherein protection is against a microbial infection.

116. (Original) The method of claim 115 wherein the microbial infection is a malaria infection.

117. (Original) The method of claim 115 wherein the microbial infection is a tuberculosis infection.

118. (Currently amended) A method of protecting a subject against an immune disease or an inflammation which comprises administering an immunoinhibitory amount of a compound according to claim ~~205~~ 206.

119. (Original) The method of claim 118 where said protection is against an autoimmune disease.

120. (Original) The method of claim 119 wherein said autoimmune disease is diabetes.

121. (Original) The method of claim 119 wherein said autoimmune disease is asthma, eczema, multiple sclerosis or rheumatoid arthritis.

122. (Original) The method of claim 118 where said protection is against inflammation.

123. (Previously presented) The method of claim 107 further comprising administering a pharmaceutically effective amount of at least one immunomodulatory agent which is not one of said compounds.

124. (Original) The method of claim 123, where at least one such immunomodulatory agent is an immunogen.

125. (Original) The method of claim 123, where at least one

such immunomodulatory agent is an adjuvant.

126. (Original) The method of claim 125, where said adjuvant is selected from the group consisting of lipid A, lipid A analogues, CpG-containing oligonucleotides, muramyl dipeptides, sitosterols, alum, and QS-21.

127. (Previously presented) The composition of claim 107, further comprising a pharmaceutically effective amount of at least one antiviral, antibacterial, antiparasitic or antitumor agent other than said compound.

128. (Currently Amended) The compound of claim ~~205~~ 206 which has immunostimulatory activity.

129. (Original) A method of stimulating the immune system of a mammalian subject which comprises administering to said subject an immunostimulatory amount of the compound of claim 128.

130. (Original) The method of claim 129 which further comprises administering to the subject an immunologically effective amount of an immunogen, the immune response to said immunogen being enhanced by said compound.

131. (Original) The method of claim 130 in which the immunogen is a disease-associated immunogen and the subject suffers from that disease.

132. (Original) The method of claim 131 in which the immunogen is a tumor-associated immunogen.

133. (Previously presented) The method of claim 130 in which

the immunogen comprises a carbohydrate epitope.

134. (Original) The method of claim 133 in which the immunogen comprises a Tn, TF or sialyl-Tn epitope.

135. (Previously presented) The method of claim 130 in which the immunogen comprises a peptide epitope.

136. (Original) The method of claim 135 in which the immunogen comprises a MUC1 epitope.

137. (Previously presented) The method of claim 129 in which the compound is delivered by means of a liposomal formulation.

138. (Previously presented) The method of claim 129 in which the immunogen comprises a strongly lipophilic group.

139. (Previously presented) The method of claim 129 in which the immunogen is delivered by means of a liposomal formulation.

140-142 (Cancelled).

143. (Previously Presented) The compound of claim 1 which has a molecular weight of less than 10,000 daltons.

144. (Previously Presented) The compound of claim 143 which has a molecular weight less than 5,000 daltons.

145. (Previously Presented) The compound of claim 143 which has a molecular weight , less than 2,500 daltons.

146. (Previously Presented) The compound of claim 143 which

has a molecular weight less than 1,000 daltons.

147. (Cancelled)

148. (Previously Presented) The compound of claim 1 in which R is an organic moiety comprising at least one carbohydrate moiety and Ch is oxygen.

149. (Previously Presented) The compound of claim 148 in which the carbohydrate moiety is galactose.

150. (Previously Presented) The compound of claim 1 in which A comprises at least one carbon-carbon double bond.

151. (Previously Presented) The compound of claim 1 in which A comprises at least one hydroxyl group.

152. (Previously Presented) The compound of claim 1 in which A is  $\text{-C(OH)-C=C-(CH}_2\text{)}_{12}\text{-CH}_3$ .

153. (Previously Presented) The compound of claim 1 in which Ch is oxygen and R2 is hydrogen.

154. (Previously Presented) The compound of claim 1 in which R3 is  $\text{-C(=O)-R3'}$ , and R3' is a polyunsaturated moiety.


155. (Previously Presented) The compound of claim 154 in which R3' comprises at least two methylene-interrupted double bonds.

156. (Previously Presented) The compound of claim 155 in which R3' is an (n-6) methylene-interrupted polyunsaturated moiety.

157. (Previously Presented) The compound of claim 156 in which



R3' is



158. (Previously Presented) The compound of claim 1 in which

R is galactose,

Ch is oxygen,

R2 is hydrogen,

R3 is  $-\text{C}(=\text{O})-\text{R3}'$ , where

R3' is  $-(\text{CH}_2)_3-(\text{CH}=\text{CH}-\text{CH}_2)_4-(\text{CH}_2)_3-\text{CH}_3$ , and

A is  $-\text{CH}(\text{OH})-\text{CH}=\text{CH}-(\text{CH}_2)_{12}-\text{CH}_3$ .

159 (Previously Presented). The compound of claim 1, wherein R comprises at least one carbohydrate moiety.

160 (Previously Presented). The compound of claim 159 wherein R is a carbohydrate moiety.

161 (Previously Presented). The compound of claim 160 wherein R is a carbohydrate moiety consisting of 1-20 sugar units.

162 (Previously Presented). The compound of claim 160 wherein R is a carbohydrate moiety consisting of 1-6 sugar units.

163 (Previously Presented). The compound of claim 160 wherein R is the carbohydrate moiety of a naturally occurring glycosphingolipid or glycosylceramide, or the carbohydrate epitope of a naturally occurring antigen.

164 (Previously Presented). The compound of claim 160 wherein R is the carbohydrate moiety of a naturally occurring glycosylceramide.

165 (Previously Presented). The compound of claim 95 wherein the inner sugar unit is galactose or glucose.

166 (Previously Presented). The compound of claim 165 wherein the carbohydrate moiety consists of 1-6 sugar units.

167 (Previously Presented). The compound of claim 165 wherein the carbohydrate moiety consists of 1-5 sugar units.

168 (Previously Presented). The compound of claim 167 wherein R is the carbohydrate moiety of a naturally occurring glycosylceramide.

169 (Previously Presented). The compound of claim 167 wherein Ch is oxygen and R2 is hydrogen.

170 (Previously Presented). The compound of claim 168 wherein Ch is oxygen and R2 is hydrogen.

171 (Previously Presented). The compound of claim 1 wherein R is galactose, Ch is oxygen, and R2 is hydrogen.


172 (Previously Presented). The compound of claim 169 wherein R3 is -C(=O)-R3', and R3' is a polyunsaturated moiety that is a hydrocarbon.

173 (Previously Presented). The compound of claim 172 wherein R3 is characterized by 10-40 carbon atoms and R3' is characterized by 2-10 olefinic bonds.


174 (Previously Presented). The compound of claim 173 wherein all olefinic double bonds of R3' belong to methylene-interrupted pairs of olefinic double bonds.

175 (Previously Presented). The compound of claim 174 wherein R3' comprises  $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}(\text{CH})_4-$ .

176 (Previously Presented). The compound of claim 169 wherein R3 is selected from the group consisting of




and



wherein  $k = 0$  to 30,  $0$  to 30,  $n = 0$  to 10, and M is  $\text{CH}_2$  or CO.

177 (Previously Presented). The compound of claim 169 wherein R3 is




178 (Previously Presented). The compound of claim 177, wherein  $k=3$ ,  $n=2$ , and  $m=4$ .

179 (Previously Presented). The compound of claim 169 wherein R3' is  $-\text{C}(=\text{O})-\text{CH}_2-\text{CH}(-\text{O}-\text{M}-(\text{CH}_2)_m-(\text{CH}=\text{CH})_n-(\text{CH}=\text{CHCH}_2)_p-\text{CH}_3)-(\text{CH}_2)_k-\text{CH}_3$ , wherein M is  $\text{CH}_2$  or CO; k and m are independent integers with values from 0 to 30, and n and p are independent integers with values from 0 to 10.

180 (Previously Presented). The compound of claim 169 wherein R3 is  $-\text{C}(=\text{O})-\text{R}3'$  and R3' is alkanyl or polyunsaturated alkenyl or  $-\text{CH}(-\text{O}-\text{alkanyl})-\text{alkanyl}$ .

181 (Previously Presented). The compound of claim 180 wherein said alkanyl and alkenyl of R3' individually do not exceed 25 carbon atoms.

182 (Previously Presented). The compound of claim 169 where the R3 therein has the structure



183 (Previously Presented). The compound of claim 171 wherein R3 is -C(=O)-R3', and R3' is a polyunsaturated moiety that is a hydrocarbon.

184 (Previously Presented). The compound of claim 183 wherein R3 is characterized by 10-40 carbon atoms and R3' is characterized by 2-10 olefinic bonds.

185 (Previously Presented). The compound of claim 184 wherein all olefinic double bonds of R3' belong to methylene-interrupted pairs of olefinic double bonds.

186 (Previously Presented). The compound of claim 185 wherein R3' comprises -CH=CH-CH2-CH-CH)4-.

187 (Previously Presented). The compound of claim 169 wherein A is -CH2OH, -CHOH-alkanyl, -CHOH-alkenyl, -CHOH-hydroxyalkanyl or -CHOH-hydroxyalkenyl.

188 (Previously Presented). The compound of claim 187 wherein A is -CH2OH.

189 (Previously Presented). The compound of claim 187 wherein A is -CHOH-alkanyl, -CHOH-alkenyl, -CHOH-hydroxyalkanyl or -CHOH-hydroxyalkenyl.

190 (Previously Presented). The compound of claim 189 wherein said alkanyl, alkenyl, hydroxyalkanyl or hydroxyalkenyl of A does not exceed 25 carbon atoms.

~~190~~ 191 (Currently Amended). The compound of claim 187 wherein A is -CHOH-alkenyl or -CHOH-hydroxyalkenyl.

~~191~~ 192 (Currently Amended). The compound of claim ~~190~~ 191 wherein A is characterized by a single olefinic double bond.

~~192~~ 193 (Currently Amended). The compound of claim ~~191~~ 192 wherein A is -CHOH-CH=CH-alkanyl.

~~193~~ 194 (Currently Amended). The compound of claim ~~192~~ 193 wherein A is  $\text{CHOH-CH=CH}(\text{CH}_2)_i \text{CH}_3$ , wherein i is 6 to 20.

~~194~~ 195 (Currently Amended). The compound of claim ~~193~~ 194 wherein i is 12.

~~195~~ 196 (Currently Amended). The compound of claim 169 wherein A is -CHOH-R1 and R1 is a substitution group selected from the group consisting of

- (a)  $-\text{CH}_2(\text{CH}_2)_i \text{CH}_3$ ,
- (b)  $-\text{CH=CH}(\text{CH}_2)_i \text{CH}_3$ ,
- (c)  $-\text{CH}(\text{OH})(\text{CH}_2)_i \text{CH}_3$ ,
- (d)  $-\text{CH}_2(\text{CH}_2)_i \text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ , and
- (e)  $-\text{CH}(\text{OH})(\text{CH}_2)_i \text{CH}(\text{CH}_3)_2$ ,

wherein i is an integer with values from 6 to 20.

~~196~~ 197 (Currently Amended). The compound of claim 189 wherein said alkanyl, alkenyl, hydroxyalkanyl or hydroxyalkenyl of A is characterized by 8 to 25 carbon atoms.

~~197~~ 198 (Currently Amended). The compound of claim ~~196~~ 197 wherein said hydroxyalkanyl or hydroxyalkenyl is characterized by a single hydroxyl group.

~~198~~ 199 (Currently Amended). The compound of claim 171

wherein A is -CH<sub>2</sub>OH, -CHOH-alkanyl, -CHOH-alkenyl, -CHOH-hydroxyalkanyl or -CHOH-hydroxyalkenyl.

~~199~~ 200 (Currently Amended). The compound of claim ~~198~~ 199 wherein A is -CH<sub>2</sub>OH.

~~200~~ 201 (Currently Amended). The compound of claim 199 wherein A is -CHOH-alkanyl, -CHOH-alkenyl, -CHOH-hydroxyalkanyl or -CHOH-hydroxyalkenyl.

~~201~~ 202 (Currently Amended). The compound of claim 189 wherein R<sub>3</sub> is -C(=O)-R<sub>3</sub>', and R<sub>3</sub>' is a polyunsaturated moiety that is a hydrocarbon.

~~202~~ 203 (Currently Amended). The compound of claim ~~201~~ 202 wherein R<sub>3</sub> is characterized by 10-40 carbon atoms and R<sub>3</sub>' is characterized by 2-10 olefinic bonds.

~~203~~ 204 (Currently Amended). The compound of claim ~~202~~ 203 wherein all olefinic double bonds of R<sub>3</sub>' belong to methylene-interrupted pairs of olefinic double bonds.

~~204~~ 205 (Currently Amended). The compound of claim ~~203~~ 204 wherein R<sub>3</sub>' comprises -CH=CH-CH<sub>2</sub>-CH-CH)<sub>4</sub>-.

~~205~~ 206 (Currently Amended). The compound of claim 189 wherein R<sub>3</sub> is -C(=O)-R<sub>3</sub>', and R<sub>3</sub>' is a polyunsaturated moiety that is a hydrocarbon.

~~206~~ 207 (Currently Amended). The compound of claim ~~205~~ 231 wherein R<sub>3</sub> is characterized by 10-40 carbon atoms and R<sub>3</sub>' is characterized by 2-10 olefinic bonds.

~~207~~ 208 (Currently Amended). The compound of claim ~~206~~ 207 wherein all olefinic double bonds of R<sub>3</sub>' belong to methylene-interrupted pairs of olefinic double bonds.

~~208~~ 209 (Currently Amended). The compound of claim ~~207~~ 208 wherein R<sub>3</sub>' comprises -CH=CH-CH<sub>2</sub>-CH-CH)<sub>4</sub>-.

~~209~~ 210 (Currently Amended). The compound of claim ~~200~~ 201 wherein said alkanyl, alkenyl, hydroxyalkanyl or hydroxyalkenyl of A is characterized by 8 to 25 carbon atoms.

~~210~~ 211 (Currently Amended). The compound of claim ~~209~~

210 wherein said hydroxyalkanyl or hydroxyalkenyl is characterized by a single hydroxyl group.

~~211~~ 212 (Currently Amended). The compound of claim ~~209~~ 210 wherein A is -CHOH-alkenyl or -CHOH-hydroxyalkenyl.

~~212~~ 213 (Currently Amended). The compound of claim ~~211~~ 212 wherein A is characterized by a single olefinic double bond.

~~213~~ 214 (Currently Amended). The compound of claim ~~212~~ 213 wherein A is -CHOH-CH=CH-alkanyl.

~~214~~ 215 (Currently Amended). The compound of claim ~~211~~ 212 wherein R3 is -C(=O)-R3', and R3' is a polyunsaturated moiety that is a hydrocarbon.

~~215~~ 216 (Currently Amended). The compound of claim ~~214~~ 215 wherein R3 is characterized by 10-40 carbon atoms and R3' is characterized by 2-10 olefinic bonds.

~~216~~ 217 (Currently Amended). The compound of claim ~~215~~ 216 wherein all olefinic double bonds of R3' belong to methylene-interrupted pairs of olefinic double bonds.

~~217~~ 218 (Currently Amended). The compound of claim ~~216~~ 217 wherein R3' comprises -CH=CH-CH<sub>2</sub>-CH-CH)<sub>4</sub>-.

~~218~~ 219 (Currently Amended). The compound of claim 1, wherein all spacers are -O- or -C(=O)-.

220 (New). The compound of claim 171 wherein R3 is -C(=O) (CH<sub>2</sub>)<sub>k</sub> (CH=CHCH<sub>2</sub>)<sub>2</sub> (CH=CHCH<sub>2</sub>)<sub>n</sub> (CH<sub>2</sub>)<sub>m</sub> CH<sub>3</sub> wherein k = 0 to 30, m = 0 to 30, and n = 0 to 10.


221 (New). The compound of claim 189 wherein R3 is -C(=O) (CH<sub>2</sub>)<sub>k</sub> (CH=CHCH<sub>2</sub>)<sub>2</sub> (CH=CHCH<sub>2</sub>)<sub>n</sub> (CH<sub>2</sub>)<sub>m</sub> CH<sub>3</sub> wherein k = 0 to 30, m = 0 to 30, and n = 0 to 10.

222 (New). The compound of claim 191 wherein R3 is -C(=O) (CH<sub>2</sub>)<sub>k</sub> (CH=CHCH<sub>2</sub>)<sub>2</sub> (CH=CHCH<sub>2</sub>)<sub>n</sub> (CH<sub>2</sub>)<sub>m</sub> CH<sub>3</sub> wherein k = 0 to 30, m = 0 to 30, and n = 0 to 10.

223 (New). The compound of claim 193 wherein R3 is -C(=O) (CH<sub>2</sub>)<sub>k</sub> (CH=CHCH<sub>2</sub>)<sub>2</sub> (CH=CHCH<sub>2</sub>)<sub>n</sub> (CH<sub>2</sub>)<sub>m</sub> CH<sub>3</sub>


wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

224 (New). The compound of claim 194 wherein R3 is




wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

225 (New). The compound of claim 196 wherein R3 is




wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

226 (New). The compound of claim 197 wherein R3 is




wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

227 (New). The compound of claim 201 wherein R3 is




wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

228 (New). The compound of claim 210 wherein R3 is




wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

229 (New). The compound of claim 212 wherein R3 is







wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

230 (New). The compound of claim 213 wherein R3 is



wherein  $k = 0$  to  $30$ ,  $m = 0$  to  $30$ , and  $n = 0$  to  $10$ .

231 (New). The compound of claim 171 wherein A is -CHOH-R1 and R1 is a substitution group selected from the group consisting of



wherein  $i$  is an integer with values from 6 to 20.